Floatz logo

13 assets in Adenosquamous Lung Carcinoma

Therapeutic assets addressing Adenosquamous Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
Adenosquamous Lung Carcinoma
Barbara Ann Karmanos Cancer InstituteP3BB (70)
Carboplatin
Adenosquamous Lung Carcinoma
NRG OncologyP3BB (69)
Cyclophosphamide
Adenosquamous Lung Carcinoma
H. Lee Moffitt Cancer Center and Research InstituteP2B (63)
Docetaxel
Adenosquamous Lung Carcinoma
Wake Forest University Health SciencesP2B (62)
Nivolumab
Adenosquamous Lung Carcinoma
National Cancer Institute (NCI)P2/3B (62)
Etoposide
Adenosquamous Lung Carcinoma
Barbara Ann Karmanos Cancer InstituteP2B (60)
Fludarabine
Adenosquamous Lung Carcinoma
H. Lee Moffitt Cancer Center and Research InstituteP2B (59)
Ipilimumab
Adenosquamous Lung Carcinoma
National Cancer Institute (NCI)P2/3B (57)
Pegfilgrastim
Adenosquamous Lung Carcinoma
Wake Forest University Health SciencesP2B (57)
esk981
Adenosquamous Lung Carcinoma
University of Michigan Rogel Cancer CenterP2CCC (53)
Nivestim
Adenosquamous Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Young Til
Adenosquamous Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Neoantigen Specific Tcr-T Cell Drug Product
Adenosquamous Lung Carcinoma
Alaunos TherapeuticsP1/2CCC (48)